SynthesisCardiology2026
Role of Adrenomedullin as a Prognostic Biomarker in Acute Heart Failure Patients: A Systematic Review and Meta-Analysis.
Synthesis in Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionResidual congestion is associated with a high rehospitalization rate in acute heart failure (HF) patients. This study aimed to evaluate the role of adrenomedullin (mid-regional pro-adrenomedullin [MR-pro ADM] and bioactive adrenomedullin [bio-ADM]) as a prognostic marker of tissue congestion with clinical outcomes in acute HF patients.
methodsThree databases were systematically searched until November 2024 to include both observational and post hoc clinical trial studies that suit the research question. Outcomes assessed are clinical outcomes of in-hospital mortality, composite outcome of all-cause mortality and major adverse cardiovascular events (MACEs), and HF rehospitalization. Statistical analyses conducted are pooled hazard ratio (HR), correlation coefficient, and area under the curve with a random-effects model.
resultsTwenty-one studies of 18,110 patients with low to medium risk of bias are included of which 20 of them are prospective cohort studies. Both MR-pro ADM and bio-ADM measured at admission or discharge are associated with a statistically significant increasing risk of composite outcome, MACE outcome, and all-cause mortality (HR 1.17-2.72). MR-pro ADM is also associated with a statistically significant increasing risk of in-hospital mortality and HF rehospitalization (HR 1.72-2.20). Bio-ADM measured at discharge is found to have a better prognostic value for all-cause mortality outcome than bio-ADM measured at admission (HR 1.90 and 1.17, respectively, p 0.007). MR-pro ADM showed a strong and moderate linear correlation with bio-ADM and NT-proBNP (R 0.784, 0.461, respectively).
conclusionMR-pro ADM and bio-ADM are both reliable prognostic markers in acute HF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.